Dublin, Oct. 04, 2017 -- The "Proteomics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Most commonly used technologies are 2D gel electrophoresis for protein separation and analysis of proteins by mass spectrometry. Microanalytical protein characterization with multidimentional liquid chromatography/mass spectrometry improves the throughput and reliability of peptide mapping. Matrix-Assisted Laser Desorption Mass Spectrometry (MALDI-MS) has become a widely used method for determination of biomolecules including peptides, proteins.
Functional proteomics technologies include yeast two-hybrid system for studying protein- protein interactions. Establishing a proteomics platform in the industrial setting initially requires implementation of a series of robotic systems to allow a high-throughput approach for analysis and identification of differences observed on 2D electrophoresis gels. Protein chips are also proving to be useful.
Proteomic technologies are now being integrated into the drug discovery process as complimentary to genomic approaches. Toxicoproteomics, i.e. the evaluation of protein expression for understanding of toxic events, is an important application of proteomics in preclincial drug safety. Use of bioinformatics is essential for analyzing the massive amount of data generated from both genomics and proteomics.
Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics.
Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 29 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 224 of these are profiled in the report with 457 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2016 and are projected to years 2021 and 2026. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
8. Oncoproteomics
9. Neuroproteomics
10. Proteomics Markets
11. Future of Proteomics
12. References
Part II: Companies
11. Companies involved in developing proteomics
For more information about this report visit https://www.researchandmarkets.com/research/lbpchk/proteomics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Proteomics


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 



